STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Point72 and Steven A. Cohen Disclose 4.33M Shares, 5.0% of SNDX

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Point72 entities and Steven A. Cohen report a 5.0% stake in Syndax Pharmaceuticals (SNDX). As of the close of business on August 15, 2025, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen each report beneficial ownership of 4,327,952 shares of Syndax common stock, representing 5.0% of the class. The filing shows no sole voting or dispositive power and reports shared voting and shared dispositive power of 4,327,952 shares. The statement is filed jointly pursuant to a Joint Filing Agreement (Exhibit 99.1). The issuer's principal executive office is listed at 730 Third Avenue, 9th Floor, New York, NY 10017.

Positive

  • Institutional ownership disclosed: Point72 and affiliates report a clear 5.0% stake, improving transparency for investors
  • Joint filing and Exhibit 99.1: Formal joint disclosure clarifies reporting responsibilities among related parties

Negative

  • No sole voting or dispositive power: The reporting persons claim only shared control, limiting their unilateral influence
  • Position size limited to 5.0%: Stake is material but not large enough alone to indicate control or immediate governance changes

Insights

TL;DR: A 5.0% shared stake by Point72 and Mr. Cohen is material but not a controlling position; it signals meaningful ownership without sole control.

The filing documents a 4,327,952-share position representing exactly 5.0% of Syndax's common stock held through Point72-managed vehicles as of August 15, 2025. Reported rights are exclusively shared voting and shared dispositive power, with no sole voting or dispositive authority claimed. The joint filing and Exhibit 99.1 indicate coordinated disclosure rather than an acquisition intended to change control. For investors, this is a visible institutional stake that could increase monitoring and engagement but, based solely on this filing, does not indicate shifts in board control or governance.

TL;DR: Joint filing and shared powers point to coordinated ownership; not a standalone controlling block.

The Schedule 13G shows Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen jointly reporting beneficial ownership of 4,327,952 shares (5.0%). The registrants explicitly report shared voting and dispositive power and disclaim sole control. The inclusion of a Joint Filing Agreement as Exhibit 99.1 formalizes joint reporting responsibilities. From a governance perspective, a 5.0% passive/common reporting stake can prompt engagement but, per the filing language, is not presented as an effort to influence or change issuer control.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/18/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/18/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/18/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

How many Syndax (SNDX) shares does Point72 report owning?

Point72 entities and Steven A. Cohen report beneficial ownership of 4,327,952 shares of Syndax common stock.

What percentage of Syndax does the reported position represent?

The reported shares represent 5.0% of the outstanding common stock as of the close of business on August 15, 2025.

Does Point72 or Steven A. Cohen have sole voting or dispositive power over the shares?

No. The filing reports 0 sole voting power and 0 sole dispositive power, and 4,327,952 shares of shared voting and shared dispositive power.

Is this filing a Schedule 13G or 13D and what does that imply?

This document is a Schedule 13G, indicating a passive or qualifying institutional reporting stance rather than an acquisition seeking to change control.

Where can I find the Joint Filing Agreement referenced in the filing?

The Joint Filing Agreement is included as Exhibit 99.1 to this Schedule 13G.
Syndax Pharmaceuticals Inc

NASDAQ:SNDX

SNDX Rankings

SNDX Latest News

SNDX Latest SEC Filings

SNDX Stock Data

1.77B
85.79M
1.29%
120.98%
24.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK